Nov 28, 2013, 06.58 PM IST
As per the licensing agreement, Helperby will take the compound through further clinical trials, approvals and into commercialisation, it added.
Like this story, share it with millions of investors on M3
Cadila Pharma inks pact with UK based Helperby Therapeutics
As per the licensing agreement, Helperby will take the compound through further clinical trials, approvals and into commercialisation, it added.
Like this story, share it with millions of investors on M3
Cadila Pharma inks pact with UK based Helperby Therapeutics
As per the licensing agreement, Helperby will take the compound through further clinical trials, approvals and into commercialisation, it added.
Also read: Will Wockhardt's loss be Dr Reddy's gain? Analysts think so
"Global market size of antibiotics is estimated to be around USD 69 billion," Cadila Pharmaceuticals said in a statement.
As per the licensing agreement, Helperby will take the compound through further clinical trials, approvals and into commercialisation, it added.
Helperby will supply Cadila Pharmaceuticals with antibiotic resistance breakers whilst Cadila Pharmaceuticals will develop the combinations with old antibiotics, the company said.
The company's however did not give any details about the financials.
Commenting on the development, Cadila Pharmaceuticals Chairman and Managing Director Rajiv I Modi said: "Cadila Pharmaceuticals' collaboration with Helperby can help the mankind win the battle against the microbes and hopefully save millions of lives in coming years."
When an antibiotic resistance breaker is combined with an old obsolete antibiotic, it can rejuvenate it and make it active against highly resistant bacteria, the company said.
Cadila Health stock price
On November 28, 2013, Cadila Healthcare closed at Rs 734.25, down Rs 0.8, or 0.11 percent. The 52-week high of the share was Rs 924.60 and the 52-week low was Rs 631.00.
The company's trailing 12-month (TTM) EPS was at Rs 34.58 per share as per the quarter ended September 2013. The stock's price-to-earnings (P/E) ratio was 21.23. The latest book value of the company is Rs 142.20 per share. At current value, the price-to-book value of the company is 5.16.
Anda sedang membaca artikel tentang
Cadila Pharma inks pact with UK based Helperby Therapeutics
Dengan url
http://gayafashionshow.blogspot.com/2013/11/cadila-pharma-inks-pact-with-uk-based.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Cadila Pharma inks pact with UK based Helperby Therapeutics
namun jangan lupa untuk meletakkan link
Cadila Pharma inks pact with UK based Helperby Therapeutics
sebagai sumbernya
0 komentar:
Posting Komentar